The Tamiflu Timeline

A timeline of key links and articles, in response to the drugs company Roche not publishing all clinical trial data on Tamiflu and more relating to the #AllTrials campaign.

1,919 total views
As seen on
  1. 17th April 2014
  2. 14th April 2014
  3. 13th April 2014
  4. "This story raised a number of red flags for me from the beginning. I’m not an epidemiologist but the way this has been reported and the dramatis personae had me looking a lot further than the abstract. And all is not what it may seem. " Blogger -
  5. 11th April 2014
  6. "The lack of scientific consensus is an important hurdle to optimizing public health response to outbreaks of (seasonal and pandemic) influenza, and thus may jeopardize the well-being of patients worldwide. In the aim to resolve this public health issue, a multidisciplinary group of scientific experts had developed a statistical analysis plan for oseltamivir data during the first Multiparty Group for Advice on Science meeting (18 June 2013, Brussels). The initiative was taken by four leading academics (Prof. Ab Osterhaus, Prof. Arnold Monto, Prof. Menno de Jong and Prof. Rich Whitley), who, together with scientific experts from various disciplines, have analysed and discussed study data provided by Roche, with complimentary research data provided by Prof. Terho Heikinnen, Prof. Nelson Lee, Prof. Allison McGeer, Prof. Jonathan Van-Tam and Prof. Frederick Hayden."  David De Pooter, MUGAS
  7. 10th April 2014

    "This week sees the publication of the updated Cochrane systematic review on the neuraminidase inhibitors oseltamivir and zanamivir.1 The review, which is also reported in two papers published in The BMJ,2 3 provides the most complete analysis so far of what is known from randomised trials about the effectiveness and safety of these antiviral drugs." Elizabeth Loder, Clinical Editor, The BMJ; David Tovey, Editor-in-Chief, The Cochrane Library; Fiona Godlee, Editor-in-Chief, The BMJ
  8. "They also found worrying side-effects in people taking it to prevent flu, which had not been fully disclosed, including psychiatric and kidney problems. "There is no credible way these drugs could prevent a pandemic," said Carl Heneghan, professor of evidence-based medicine at Oxford University and one of the team. They are now calling for the WHO to review its advice to countries and for the UK government not to renew its stockpile when the drugs go out of date." Sarah Boseley, The Guardian
  9. "RCTs are the gold standard of drug assessment. The downside in this case is that these RCTs include only people who are otherwise healthy except for relatively mild winter flu." Debora MacKenzie, New Scientist